Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles

Nakata, Hiroshi; Miyazaki, Tatsuhiko; Iwasaki, Tomoyuki; Nakamura, Atsushi; Kidani, Teruki; Sakayama, Kenshi; Masumoto, Junya; Miura, Hiromasa

doi:10.3892/or.2015.3761

Cited by 13 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morphology. The morphology of CDDP/DNA CLPNs, and CDDP PNPs was examined by transmission electron microscopy (TEM) (JEM-200CX; JEOL Co., Ltd., Tokyo, Japan) (23). Samples were stained at room temperature with freshly prepared and sterile-filtered 1% (w/v) phosphotungstic acid aqueous solution.…”

Section: Characterizationmentioning

confidence: 99%

Core-shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers

Zhang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

Pediatric head and neck cancers account for overall 12% of all pediatric cancers. Despite recent advances in therapeutic modalities, children with tumor metastasis have poor prognosis. Therefore, there is an unmet need for new and effective treatment modalities for pediatric head and neck cancers. The present study describes a simple and efficient method for fabrication of cationic lipid‑polymer hybrid nanoparticles (CLPNs) for co‑delivery of cisplatin (CDDP) and DNA (CDDP/DNA CLPNs) for the therapy of childhood head and neck cancers. CDDP/DNA CLPNs were prepared by the modified double emulsion solvent evaporation method with self‑assembly. CDDP‑loaded CLPNs (CDDP CLPNs), CDDP-loaded polymeric nanoparticles (PNPs) (CDDP PNPs), and DNA‑loaded Lipofectamine® 2000 (DNA LIPO) were also prepared for comparison. The results illustrated that the concentration of the cationic lipid has influence on the characteristics of CLPNs. In vitro anticancer effect, in vitro transfection efficiency, in vivo antitumor and gene delivery efficacy of CDDP/DNA CLPNs have advantages over other formulations tested. In conclusion, outstanding delivery ability of CLPNs for both CDDP and DNA could combine the therapeutic efficiency of both drug and gene for the treatment of pediatric rhabdomyosarcoma (RMS).

show abstract

Section: Characterizationmentioning

confidence: 99%

Core-shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers

Zhang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Several studies have formulated IFO in nanocarriers including solid-lipid nanoparticle, nanostructured lipid nanoparticles, self-assembled polymeric nanoparticles, span 80 nano-vesicles, and selfmicroemulsifying drug delivery systems. [8][9][10][11][12] NEs are considered potential carriers for the essential III-V were inoculated with EAC for 48 hours. Group III (IFO) included EAC-bearing mice treated with IFO at a dose of 60 mg/kg/d (I.P.…”

Section: Introductionmentioning

confidence: 99%

Incorporating ifosfamide into salvia oil-based nanoemulsion diminishes its nephrotoxicity in mice inoculated with tumor

2019

View full text Add to dashboard Cite

Introduction: Nephrotoxicity is one of the major side effects of the chemotherapeutic drug, ifosfamide (IFO). In this study, IFO was solubilized in nanoemulsion (NE) containing salvia (SAL) essential oil to investigate its adverse side effects in mice. Methods: One hundred female Swiss albino mice (n = 20/group) were split into five groups. Group I (Normal) received saline solution (0.9% (w/v) NaCl) while groups II-V were intraperitoneally (I.P.) injected with 2.5 × 106 Ehrlich ascetic carcinoma (EAC) cells/mouse. Group II (EAC) represented the untreated EAC-bearing mice. Group III (IFO) was treated with IFO at a dose of 60 mg/kg/d (I.P. 0.3 mL/mouse). Group IV (SAL) was treated with 0.3 mL blank NE-based SAL oil/mouse. Group V (SAL-IFO) was treated with IFO, loaded in 0.3 mL of blank SAL-NE, at a dose of 60 mg/kg/d (I.P. 0.3 mL/mouse). Groups III-V were treated for three consecutive days. Results: There was a double increase in the survival percentage of the SAL-IFO group (60%) relative to the IFO group (30%). Renal damage with the presence of Fanconi syndrome was indicated in the IFO group through a significant elevation in the levels of serum creatinine, blood urea nitrogen, urine bicarbonate, and phosphate in addition to a reduced level of glucose compared to the normal group. On the other hand, the administration of SAL-IFO into the mice reversed this effect. Additionally, the oxidative stress in the kidney tissues of the SAL-IFO group was ameliorated when compared to the IFO group. Conclusion: Incorporating IFO into SAL-NE has protected the kidneys from the damage induced by IFO.

show abstract

“…As the murine osteosarcoma therapeutic model, C3H/ HeJ mice underwent transplanted murine osteosarcoma cell line LM8. The detailed procedures were described in the original paper [34].…”

Section: Caffeine-potentiated Chemotherapy Using Span 80 Nano-vesiclementioning

confidence: 99%

“…The population of apoptotic and/or necrotic cells was measured as M1 and was shown inTable 2. [Reprinted with permission from Ref [34]…”

mentioning

confidence: 99%

Development of Tumor-Specific Caffeine-Potentiated Chemotherapy Using Span 80 Nano-Vesicles DDS

Miyazaki¹,

Nakata²,

Kato³

2017

The Question of Caffeine

Self Cite

View full text Add to dashboard Cite

Osteosarcoma cases with metastasis have poor prognosis in general. Recently, caffeinepotentiated chemotherapy, which is chemotherapy with caffeine dosage against malignancies, has manifested potently high efficacy as well as diverse effects. Recently, we demonstrated that nonionic vesicles prepared from Span 80 have promising physicochemical properties, which let them an attractive option besides the common liposomes. Here, we manifested the tumor-specific caffeine-potentiated chemotherapy against osteosarcoma in murine model employing a novel drug delivery system (DDS) with Span 80 nano-vesicles. C3H/HeJ mice underwent transplantation of LM8 osteosarcoma cell line and then were doped with therapeutic agents. Caffeine was employed as an enhancer in addition to ifosfamide (IFO) as the antitumor agent. in vitro, the united administration of IV + CV revealed significant induction of tumor apoptosis in the early phase. In vivo study manifested that IV + CV-administration markedly decreased the tumor volume as well as the viable tumor area than in the other groups. No marked organ damage was observed in the IV or IV + CV groups as well as fertility injury and/or malformations in their progeny. This novel DDS might have the importance for clinical application in primary tumors as well as the metastatic osteosarcoma.

show abstract

Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles

Cited by 13 publications

References 28 publications

Core-shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers

Core-shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers

Incorporating ifosfamide into salvia oil-based nanoemulsion diminishes its nephrotoxicity in mice inoculated with tumor

Development of Tumor-Specific Caffeine-Potentiated Chemotherapy Using Span 80 Nano-Vesicles DDS

Contact Info

Product

Resources

About